OSCR

PARP4 drives tumor progression by promoting glioma cell proliferation and invasion as a potential therapeutic target.

Overview

Authors: Bingqi Lu1,2, Zhou Jing1,2, Fangyuan Wang1,2, Minghe Li1,2, Ao Huo1,2, Chenglin Zhao3,2, Zhongyu Zhao1,2, Qingyi Wang1,2, Hao Li1,2, Wulong Liang1,2, Weihua Hu1,2, Xudong Fu1,3
  1. Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China
  2. Henan Provincial Key Laboratory of Cranial Nerve Diseases, Zhengzhou University, Zhengzhou, China
  3. Department of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou University, Zhengzhou, China
Institutions: Zhengzhou University (China); Fifth Affiliated Hospital of Zhengzhou University (China); Henan Provincial People's Hospital (China)
Journal: Discover oncology, volume 17, issue 1, article 813
Dates: received 4 December 2025; accepted 6 April 2026; published online 18 April 2026
Type: Research article · Language: English
License: CC BY-NC-ND
Identifiers: DOI 10.1007/s12672-026-04980-8 · PMID 41999525 · PMCID PMC13219579 · OpenAlex W7154853159
Open access: gold, a free copy (OpenAlex)
Status: data only
Categories: human (organism), other condition (population), clinical / translational (subfield)
Methods: Statistics, Connectivity
Keywords: Glioma, PARP4, Prognosis, Migration and invasion, Therapeutic target
Topic: PARP inhibition in cancer therapy (Oncology, Medicine), according to OpenAlex
Funding: National Natural Science Foundation of China (82303029); Science and Technology Department of Henan Province (232102311134); Zhengzhou Science and Technology Innovation Project for Healthcare (2024YLZDJH027)
Citations: not cited yet (Europe PMC); 39 references in the paper

Abstract

The abstract is not reproduced here: the paper's license (CC BY-NC-ND) does not allow it. Read it in the paper, at the publisher or on Europe PMC.

Code

The paper links to its data, not to its authors' code: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Other data links

Data availability statement

The paper has a data availability statement. Its license (CC BY-NC-ND) does not allow reproducing it here; in short, from what the harvester recognized in it:

  • it points to a dataset: NCBI
  • it says that the data are available on request

Read it in the paper: doi.org/10.1007/s12672-026-04980-8.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 29 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 12 authors, 5 keywords, 3 funders, 38 references.

Cite

This paper

Lu, B., Jing, Z., Wang, F., Li, M., Huo, A., Zhao, C., Zhao, Z., Wang, Q., Li, H., Liang, W., Hu, W., & Fu, X. (2026). PARP4 drives tumor progression by promoting glioma cell proliferation and invasion as a potential therapeutic target. Discover oncology, 17(1), 813. https://doi.org/10.1007/s12672-026-04980-8

BibTeX

@article{lu2026parp4,
author = {Lu, Bingqi and Jing, Zhou and Wang, Fangyuan and Li, Minghe and Huo, Ao and Zhao, Chenglin and Zhao, Zhongyu and Wang, Qingyi and Li, Hao and Liang, Wulong and Hu, Weihua and Fu, Xudong},
title = {{PARP4 drives tumor progression by promoting glioma cell proliferation and invasion as a potential therapeutic target}},
journal = {Discover oncology},
year = {2026},
month = apr,
volume = {17},
number = {1},
pages = {813},
publisher = {Springer},
issn = {2730-6011},
doi = {10.1007/s12672-026-04980-8},
url = {https://doi.org/10.1007/s12672-026-04980-8},
pmid = {41999525},
pmcid = {PMC13219579}
}

RIS

TY - JOUR
AU - Lu, Bingqi
AU - Jing, Zhou
AU - Wang, Fangyuan
AU - Li, Minghe
AU - Huo, Ao
AU - Zhao, Chenglin
AU - Zhao, Zhongyu
AU - Wang, Qingyi
AU - Li, Hao
AU - Liang, Wulong
AU - Hu, Weihua
AU - Fu, Xudong
TI - PARP4 drives tumor progression by promoting glioma cell proliferation and invasion as a potential therapeutic target
T2 - Discover oncology
J2 - Discov Oncol
PY - 2026
DA - 2026/04/18
VL - 17
IS - 1
SP - 813
SN - 2730-6011
PB - Springer
DO - 10.1007/s12672-026-04980-8
UR - https://doi.org/10.1007/s12672-026-04980-8
LA - en
ER -

CSL-JSON

{
"id": "10.1007/s12672-026-04980-8",
"type": "article-journal",
"title": "PARP4 drives tumor progression by promoting glioma cell proliferation and invasion as a potential therapeutic target",
"container-title": "Discover oncology",
"author": [
{
"family": "Lu",
"given": "Bingqi"
},
{
"family": "Jing",
"given": "Zhou"
},
{
"family": "Wang",
"given": "Fangyuan"
},
{
"family": "Li",
"given": "Minghe"
},
{
"family": "Huo",
"given": "Ao"
},
{
"family": "Zhao",
"given": "Chenglin"
},
{
"family": "Zhao",
"given": "Zhongyu"
},
{
"family": "Wang",
"given": "Qingyi"
},
{
"family": "Li",
"given": "Hao"
},
{
"family": "Liang",
"given": "Wulong"
},
{
"family": "Hu",
"given": "Weihua"
},
{
"family": "Fu",
"given": "Xudong"
}
],
"container-title-short": "Discov Oncol",
"volume": "17",
"issue": "1",
"page": "813",
"DOI": "10.1007/s12672-026-04980-8",
"PMID": "41999525",
"PMCID": "PMC13219579",
"ISSN": "2730-6011",
"publisher": "Springer",
"URL": "https://doi.org/10.1007/s12672-026-04980-8",
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
18
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3389/fphar.2026.1797067
Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma.
Journal: Frontiers in pharmacology
In common: NCBI GEO GSE4290, clinical / translational, other condition
[2] doi:10.1186/s40644-026-01052-6 [code]
Microstructure mapping with time-dependent diffusion MRI differentiates primary central nervous system lymphoma from glioblastoma.
Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
In common: clinical / translational, other condition, 3 references
[3] doi:10.1002/adhm.202504842
Flash Assembloids: A Rapid Biofabrication of a Platform for Modeling Early Glioblastoma Invasion at the Glioblastoma-Brain Organoid Interfaces.
Journal: Advanced healthcare materials
In common: other condition, 2 references
[4] doi:10.1016/j.isci.2026.117247
Brain assembloids reveal efficacy and off target effects in high grade glioma brain cancer.
Journal: iScience
In common: clinical / translational, other condition, 1 reference
[5] doi:10.1371/journal.pone.0355902 [code]
Pericyte-derived cancer-associated fibroblasts correlate with poor survival and are enriched after chemoradiotherapy in glioblastoma.
Journal: PloS one
In common: other condition, 1 reference
[6] doi:10.3390/ijms27167240
1-Piperidine Propionic Acid Inhibits PAR2/SerpinB3 Signaling and Reduces Glioblastoma Tumor Aggressiveness.
Journal: International journal of molecular sciences
In common: other condition, 1 reference
[7] doi:10.3390/ijms27104300
A Synaptogenesis-Associated Histomorphologic Signature from H&E Whole-Slide Images Predicts Glioma Prognosis and Identifies <i>EFNB2</i>-Positive Malignant Cells as a Candidate Neuro-Glioma Communication Hub.
Journal: International journal of molecular sciences
In common: other condition, 1 reference
[8] doi:10.1007/s11060-026-05515-5
Human neural organoid modeling of diffuse midline glioma captures the complexity of patient tumors.
Journal: Journal of neuro-oncology
In common: other condition, 1 reference
[9] doi:10.21037/tcr-2026-1-0228
Phagocytic remodeling in CD74<sup>High</sup> tumor-associated macrophages during brain metastasis of lung adenocarcinoma.
Journal: Translational cancer research
In common: other condition, 1 reference
[10] doi:10.3389/fonc.2026.1771697
EMILIN-1 in the tumor microenvironment: insights from CNS tumors and beyond.
Journal: Frontiers in oncology
In common: other condition, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.